Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Resverlogix Announces Participation in Upcoming Conferences

Resverlogix
Posted on: 13 Sep 16

CALGARY, Sept. 12, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) is pleased to announce its participation in the following industry conferences in the month of September.

Rodman & Renshaw 18th Annual Global Investment Conference

Location:

New York, NY.

Date:

September 13th, 2016

Presentation Time:

2:10pm EDT

Presenting:

Mr. Donald J. McCaffrey, President & Chief Executive Office

Webcast link:

http://wsw.com/webcast/rrshq26/RVX

 

BioPharm America 9th Annual International Partnering Conference

Location:

Boston, MA.

Date:

September 14th, 2016

Presentation Time:

12:00pm EDT

Presenting:

Mr. Kenneth Lebioda, Sr. VP Business & Corporate Development

 

52nd European Association for the Study of Diabetes (EASD) Annual Meeting

Location:            

Munich, Germany

Date:       

September 14th, 2016

Presentation Time:  

12:00pm CEST

Presenting:         

Dr. Norman Wong, Chief Scientific Officer

Poster:            

"Apabetalone (RVX-208) acts on epigenetics to lower Major Adverse Cardiovascular Events (MACE) in diabetes patients with atherosclerosis via microbiome activity"

 

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Resverlogix common shares trade on the Toronto Stock Exchange (RVX.TO).

For further information please visit www.resverlogix.com.

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog

For further information please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252

For more information:
finance.yahoo.com/news/resverlogix-announces-participation-upcoming-conferences-110000072.html

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 13/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.